---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-029524"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:27:51.849106+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted

## Summary
- Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.
- Key secondary endpoint CGI-S also missed (p=0.522).
- eDSP well tolerated; most common adverse events pruritis and pyrexia.
- Company to cease clinical development of eDSP and explore available options.
- Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia.

## SEC filing metadata
- accession: 0001193125-26-029524
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/0001193125-26-029524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526029524/d61547d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-029524
- JSON: https://secwatch.observer/filing/0001193125-26-029524.json
- Plain text: https://secwatch.observer/filing/0001193125-26-029524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.